Novartis AG


  • *AstraZeneca working with academic groups and Thermo Fisher. LONDON, Jan 29- AstraZeneca said on Thursday it had struck four research agreements in the hot area of genome editing as it bets on a new "genetic scissors" technology to deliver better and more precise drugs for a range of diseases. The collaborations with Britain's Wellcome Trust Sanger Institute, the...

  • *CEO says Roche committed to Switzerland despite franc rise. While cross-town rival Novartis has said it will review its Swiss cost base, Roche Chief Executive Severin Schwan said his company had no plans to move operations. "I continue to believe that Switzerland and Basel offer a very good framework for our business," Schwan told reporters.

  • Midday movers: Lockheed Martin, Plantronics & more Tuesday, 27 Jan 2015 | 1:05 PM ET
    Wall Street subway station NYSE

    Some of Tuesday's midday movers:

  • European stocks end lower after US earning misses Tuesday, 27 Jan 2015 | 11:41 AM ET

    European markets closed down on Tuesday, after a number of Wall Street's biggest firms missed earnings expectations.

  • Novartis flags faster sales, profit growth for 2015 Tuesday, 27 Jan 2015 | 2:48 AM ET
    Joe Jimenez, CEO of Novartis, at 2015 WEF in Davos, Switzerland.

    Novartis forecast sales and profits to grow at a faster pace this year driven by recent drug successes and its portfolio overhaul.

  • *Core EPS $1.21 vs $1.18 forecast in Reuters poll. ZURICH, Jan 27- Swiss drugmaker Novartis forecast sales and profits to grow at a faster pace this year as recent drug successes and its portfolio overhaul help it weather the impact of generic competition. Novartis unveiled a transformative series of deals last year which will see it focus on a smaller number of...

  • We're looking for bolt-on acquisitions: Novartis CEO

    Joe Jimenez, CEO of Novartis, says the company is looking to carry out merger and acquisition deals in 2015 to compliment its existing businesses.

  • Novartis CEO on euro, Swiss franc effect   Tuesday, 27 Jan 2015 | 1:45 AM ET
    Novartis CEO on euro, Swiss franc effect

    Joe Jimenez, CEO of Novartis, says currency moves won't affect the growth of the underlying business.

  • NEW YORK, Jan 26- A new wave of experimental cancer drugs that directly recruit the immune system's powerful T cells are proving to be immensely effective weapons against tumors, potentially transforming the $100 billion global market for drugs that fight the disease. But top oncology researchers are concerned about the two emerging technologies, citing...

  • DUBLIN/ FRANKFURT, Jan 22- Business leaders in Europe gave a mixed welcome to the European Central Bank's moves to bolster growth and inflation in the euro area on Thursday, with many- especially in Germany- concerned the programme could delay unpopular economic reforms. "This is a step in the right direction and we'll have to watch and see how it plays out," Swiss...

  • We are funding part of ACA: Novartis CEO   Thursday, 22 Jan 2015 | 8:14 AM ET
    Joe Jimenez, CEO of Novartis, at 2015 WEF in Davos, Switzerland.

    Joe Jimenez, Novartis CEO, discusses how the move in the Swiss franc impacted his company, innovative drugs in the pipeline, and pharmaceutical pricing issues.

  • Meet Morningstar's fund managers of the year Wednesday, 21 Jan 2015 | 5:42 PM ET
    Stock performance chart on computer screen

    Here are the fund managers Morningstar considers the best of the best.

  • Jan 21- The U.S. Food and Drug Administration approved Novartis AG's injectable drug, Cosentyx, to treat adults with a moderate to severe skin disease called plaque psoriasis. Eli Lilly and Co will begin marketing its IL-17 inhibitor ixekizumab in the first half of 2015, while Amgen Inc and AstraZeneca Plc's brodalumab reported positive results from a...

  • FDA approves Novartis's psoriasis drug Wednesday, 21 Jan 2015 | 12:49 PM ET

    Jan 21- The U.S. Food and Drug Administration said it approved Novartis AG's drug to treat adults with moderate to severe plaque psoriasis.

  • WASHINGTON, Jan 20- The U.S. Supreme Court on Tuesday ruled that Teva Pharmaceutical Industries Ltd can still benefit from patent protection for top-selling multiple sclerosis drug Copaxone, dealing a blow to generic drugmakers looking to market a cheaper rival product. In a 7-2 vote, the justices sent the case back to the U.S. Court of Appeals for the Federal...

  • LONDON, Jan 16- GlaxoSmithKline is feeling the heat from the rapid growth in electronic cigarettes, with enthusiasm for the nicotine delivery devices dampening sales of the British drugmaker's patches and gum, its chief executive said. In an interview with Reuters, Andrew Witty also said he and his team had spent "a few days" exploring whether the drugmaker...

  • *Consumer more tenable as standalone business after Novartis deal. Chief Executive Andrew Witty told Reuters the group's large consumer health business would be more viable as a standalone operation following the conclusion of a $20 billion asset swap with Novartis, especially if it bought additional assets. "Post- Novartis, particularly if we did more...

  • *Bank of America, Citi fall after results. *Swiss National Bank scraps three-year-old euro cap on franc. "We're probably going to see slowing in the global economy, and it will be very difficult to sail through a global recession without getting touched," said Scott Colyer, chief executive officer of Advisors Asset Management in Monument, Colorado.

  • *Bank of America, Citi down after results. *Swiss National Bank moves to scrap 3- year euro cap on the franc. Swiss stocks traded in the United States moved higher, Credit Suisse, up 0.7 percent at $22.98 and Novartis, up 1.9 percent to $98.61, as a strengthening Swiss franc made U.S.-dollar denominated stocks cheaper.

  • Midday movers: Credit Suisse, UBS, Citigroup & more Thursday, 15 Jan 2015 | 12:42 PM ET
    Wall Street subway station NYSE

    Some of Thursday's midday movers: